Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00476268
Status:
COMPLETED
Last Update Posted:
2020-07-31
First Post:
2007-05-18
Brief Title:
Efficacy and Tolerability of BeclometasoneFormoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma
Sponsor:
Chiesi Farmaceutici SpA
Organization:
Chiesi Farmaceutici SpA
Study Overview
Official Title:
A 24-week Phase III Study to Evaluate the Efficacy and Tolerability of BeclometasoneFormoterol Single Inhaler HFA 134a-pMDI in Adult Patients With Moderate to Severe Persistent Asthma
Status:
COMPLETED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Efficacy and tolerability of the fixed combination beclometasoneformoterol in patients with moderate to severe persistent asthma
Detailed Description:
The purpose of this study is to evaluate the efficacy and tolerability of beclometasoneformoterol single inhaler in a twice daily regimen in patients with moderate to severe persistent asthma Patients are randomised to receive either beclometasoneformoterol single inhaler total daily dose BDPFF 40024 mcg or beclometasone CFC formoterol DPI total daily dose BDP 1000 mcg FF 24 mcg or beclometasone CFC total daily dose BDP 1000 mcg during 24 weeks of treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None